Insider sale notice: IDEXX Labs (NASDAQ: IDXX) files Form 144
IDEXX Laboratories (NASDAQ: IDXX) has filed a Form 144, indicating a proposed sale of Common Stock through Goldman Sachs & Co. LLC. The filing details multiple lots of Restricted Stock Units acquired as compensation between 2022 and 2026, which are now intended for sale. This notice serves as a transparency measure for potential insider disposals of securities.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) shares rose 1.30% to $553.58 on Wednesday, outperforming the broader market during a strong trading session. The S&P 500 Index and Dow Jones Industrial Average also saw significant gains. This marks the third consecutive day of gains for IDEXX Laboratories.
IDEXX SDMA Rollout Ties Earlier Kidney Detection To Valuation Debate
IDEXX Laboratories (IDXX) has integrated the SDMA kidney biomarker into its Catalyst in-clinic chemistry profiles, enabling earlier detection of kidney disease in pets without altering existing veterinary workflows. This move leverages IDEXX's established base to expand access to kidney monitoring and aligns with international veterinary guidelines. While the stock trades below analyst targets and near its estimated fair value, investors should monitor SDMA adoption and potential sensitivity to utilization slowdowns given its P/E ratio.
IDEXX Laboratories (Nasdaq:IDXX) - Stock Analysis
This report provides a comprehensive stock analysis of IDEXX Laboratories (IDXX), covering its market performance, financial health, future growth predictions, and recent news. Key highlights include its Q1 2026 revenue growth and increased full-year guidance, driven by strong diagnostics and new product integration like the SDMA kidney biomarker. The analysis also touches on analyst sentiment, insider transactions, and comparisons to competitors.
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
IDEXX Laboratories, Inc. has announced the integration of SDMA, a renal biomarker, into its Catalyst™ CLIPs, making complete kidney function evaluation part of common point-of-care chemistry profiles. Available in June in the US and Canada, this integration aims to provide veterinarians with earlier insights into kidney function loss for pets without disrupting existing workflows. The SDMA test is recognized by IRIS for early detection of chronic kidney disease and has been performed approximately 119 million times globally.
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) has released a report detailing over 20 discovery-originated drug candidates, with ten currently in active clinical trials across various phases and therapeutic areas, stemming from its antibody discovery work. The company emphasizes that these clinical assets are partner-owned, showcasing MindWalk's contribution as the foundational molecule and early development, driven by its proprietary wet-lab and AI capabilities. MindWalk highlights its robust scientific standard, supported by over 400 peer-reviewed publications and patents, which guides its integration of advanced AI including the HYFT® system and LensAI™ platform, built on a unique biological knowledge graph.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
Shares of IDEXX Laboratories Inc. (IDXX) rose 3.21% to $545.79 on Monday, outperforming the broader market. The Dow Jones Industrial Average saw a gain of 0.32%, while the S&P 500 Index experienced a slight decline of 0.07%. Despite the day's gain, the company's stock remains 29.12% below its 52-week high.
Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX
Elyxium Wealth LLC has made a significant new investment in IDEXX Laboratories, acquiring approximately 5.4 million shares valued at $3.67 billion, which now constitutes its largest holding. This investment comes after IDEXX reported strong Q4 earnings, surpassing revenue and EPS estimates, and raising its FY2026 guidance. Analysts maintain a "Moderate Buy" rating for IDEXX, with an average price target of $751.
Idexx Laboratories Shareholders Approve Governance and Meeting Reforms
Idexx Laboratories shareholders approved significant governance reforms at their May 12, 2026 annual meeting, including the declassification of the board over three years and the right for shareholders holding 25% of shares for at least a year to request special meetings. These changes aim to modestly expand shareholder rights while maintaining the company's preferred framework for such meetings. Analysts currently rate IDEXX stock as a Buy with a price target of $675.00, supported by strong profitability and cash flow, despite concerns about weak technical trends and a premium valuation.
IDEXX Laboratories, Inc. $IDXX Shares Sold by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans reduced its stake in IDEXX Laboratories (NASDAQ: IDXX) by 3.2% in the fourth quarter, selling 1,957 shares and retaining 58,581 shares valued at $39.6 million. Despite this, IDEXX reported strong quarterly results, exceeding EPS and revenue expectations with 14.3% year-over-year revenue growth. Analysts generally maintain a "Moderate Buy" rating with an average price target of $751, although some have marginally reduced their targets.
Northwestern Mutual Wealth Management Co. Increases Position in IDEXX Laboratories, Inc. $IDXX
Northwestern Mutual Wealth Management Co. significantly increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by over 63,500% in the fourth quarter, now holding 1.44 million shares valued at approximately $977.2 million. Despite this strong institutional interest and the company beating its recent EPS and revenue estimates, IDEXX stock was down 0.8%, and several analysts have recently lowered their price targets, though the consensus remains a "Moderate Buy." Insider selling by the CEO and a director also occurred, indicating mixed signals for investors.
Bessemer Group Inc. Trims Stock Position in IDEXX Laboratories, Inc. $IDXX
Bessemer Group Inc. reduced its stake in IDEXX Laboratories by 11.6% in the fourth quarter, selling 40,919 shares and holding 311,349 shares valued at $210.6 million. Despite solid earnings that beat analyst expectations, insider selling was noted, and analysts provided mixed ratings, with an average "Moderate Buy" consensus. Other institutional investors, such as Vanguard Group Inc. and Bank of New York Mellon Corp, increased their holdings in IDEXX Laboratories during the third quarter.
IDEXX (NASDAQ: IDXX) declassifies board, grants 25% special-meeting right
IDEXX Laboratories, Inc. shareholders approved significant governance changes at their 2026 annual meeting, including the declassification of the Board of Directors over three years, leading to annual elections for all directors by 2029. Additionally, shareholders granted investors holding at least 25% of the company's stock for a continuous year the right to call a special shareholder meeting. These changes were formalized with amendments to the company's Certificate of Incorporation and By-Laws, reflecting a move towards increased accountability and shareholder rights.
Karen Peacock At IDEXX Laboratories Exercises Options Worth $0
Karen Peacock, a Director at IDEXX Laboratories (NASDAQ: IDXX), exercised stock options totaling 0 shares with a transaction value of $0, according to a recent SEC filing. The company's shares were up by 0.47% at $532.0 on Friday morning, bringing the total value of Peacock's exercised (0) shares to $0. The article also provides a financial overview of IDEXX Laboratories, discussing its revenue growth, profitability, debt management, and valuation metrics, while emphasizing the relevance of insider transactions.
Capitalizing On Growth Prospects, Irene Chang Britt Acquires IDEXX Laboratories Stock Options Worth $771
Irene Chang Britt, a Board Member at IDEXX Laboratories (NASDAQ: IDXX), recently acquired 525 company stock options with an exercise price of $533.92 per share, valued at $771. This insider transaction indicates Britt's positive outlook for the stock's future performance. The article also provides a financial overview of IDEXX Laboratories, highlighting its revenue growth, debt management, and various valuation metrics.
Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0
Sam Samad, an IDEXX Laboratories Board Member, exercised company stock options worth $0 on May 14, as reported in an SEC filing. This insider activity and the company's financial metrics such as revenue growth, profitability, and valuation are analyzed, noting IDEXX's strong revenue growth and market capitalization, along with a high debt-to-equity ratio. The article also provides context on insider transactions and their significance for investors.
In A Strategic Move, Joseph L Hooley Acquires IDEXX Laboratories Stock Options Worth $771: Enhancing Valu
Joseph L Hooley, a Board Member at IDEXX Laboratories (NASDAQ: IDXX), recently acquired stock options for 525 shares, valued at $771. This insider transaction signals optimism from Hooley regarding the company's future performance. IDEXX Laboratories reported a solid 14.26% revenue growth and maintains a high gross margin, though it faces challenges in debt management and market valuation metrics.
IDEXX announces UK availability of cancer Dx panel for early detection of canine lymphoma
IDEXX has introduced its new Cancer Dx panel in the UK, designed for the early detection and diagnosis of lymphoma in canines. This innovative diagnostic tool provides veterinarians with an advanced method to identify this common cancer, allowing for timely intervention and improved patient outcomes. The launch signifies IDEXX's continued commitment to advancing veterinary diagnostics.
Director Sam Samad (NASDAQ: IDXX) receives new stock units and options grant
IDEXX Laboratories director Sam Samad was granted 234 deferred stock units and a non-qualified stock option for 525 shares on May 12, 2026, as part of his board compensation. Both awards vest in a single installment on the one-year anniversary of the grant date or the 2027 annual shareholder meeting. This transaction is a routine equity compensation event, aligning director incentives with long-term shareholder interests, and does not involve open-market trades.
IDEXX (IDXX) grants director RSUs and stock options at $533.92
IDEXX Laboratories Inc. (IDXX) director Daniel M. Junius was granted 234 restricted stock units and 525 non-qualified stock options at an exercise price of $533.92 per share on May 12, 2026. These equity awards will vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever is earlier. The grants are compensation and not open-market purchases, as detailed in the company's Form 4 SEC filing.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
IDEXX Laboratories, Inc. announced its CEO, Mike Erickson, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 27, 2026. The company also announced it will host its 2026 Investor Day on August 13, 2026, at its corporate headquarters in Westbrook, Maine. Both events will have live webcasts available for investors.
IDEXX (IDXX) director Lawrence Kingsley awarded RSUs and stock options
IDEXX Laboratories director Lawrence D. Kingsley received grants of restricted stock units (RSUs) and non-qualified stock options on May 12, 2026. These awards include RSUs for 75 and 234 shares, and stock options for 168 and 525 shares at an exercise price of $533.92. The RSUs and options will vest in one installment on the one-year anniversary of the grant date or by the 2027 annual shareholders' meeting, whichever is earlier, with options expiring in May 2036.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced that its CEO, Mike Erickson, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 27, 2026. The company also announced it will host its 2026 Investor Day on August 13, 2026, at its corporate headquarters in Westbrook, Maine. Both events will offer live audio webcasts for investors.
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026
VolitionRx (NYSE: VNRX) reported Q1 2026 revenues of $985,076 and a net loss of $6.7 million, with an operating cash outflow of $5.3 million, leaving $3.1 million in cash. The company faces "substantial doubt" about its ability to continue as a going concern due to recurring losses, negative cash flows, and significant liabilities. Funding relies on equity raises and convertible notes, with future disclosures on cash generation and commercial traction being critical for its financial sustainability.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced its CEO, Mike Erickson, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 27, 2026. The company also announced it will host its 2026 Investor Day on August 13, 2026, at its corporate headquarters in Westbrook, Maine. Webcasts for both events will be available on the company's investor relations website, with advance registration required for the in-person Investor Day.
IDEXX Laboratories stock (US45167R1041): Q1 earnings beat with 14.3% revenue growth
IDEXX Laboratories reported strong Q1 2026 results, surpassing EPS estimates by $0.06 with earnings of $3.47 and exceeding revenue expectations with a 14.3% year-over-year increase to $1.14 billion. The company also provided full-year guidance for both EPS ($14.45-$14.90) and revenue ($4.7-$4.8 billion) that aligns with consensus forecasts. This performance is attributed to its leading position in veterinary diagnostics and a "razor-razorblade" business model.
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $714.36, Implies 35% Upside
The average 12-month price target for IDEXX Laboratories, Inc. (IDXX) stock has been trimmed slightly to $714.36 from $721.5 by 11 analysts. This new target suggests a potential upside of approximately 35% from its May 13 closing price, with individual forecasts ranging from $640 to $805 per share. Despite the slight downward adjustment in the price target, the consensus analyst rating remains a "Buy" from 15 covering analysts.
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Cut to $721.5, Implies 35% Upside
The average 12-month price target for IDEXX Laboratories, Inc. (IDXX) stock has been lowered to $721.5 from $727.54, according to estimates from 12 analysts. This new target suggests a potential upside of approximately 35% from its May 12 closing price. Despite the slight target reduction, the consensus rating remains "Buy" from 16 analysts.
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 98/100
IDEXX Laboratories Inc (IDXX) shares fell 4.7% to $533.92 on May 12, 2026, marking a 21.1% year-to-date decline. Despite recent insider selling of $22.5 million, the stock appears to be modestly undervalued according to its GF Value™ of $624.70, and boasts a strong GF Score™ of 98/100, excelling in profitability, growth, and valuation. Investors are advised to consider the insider selling trend alongside the apparent undervaluation.
IDEXX Laboratories stock (US45167R1041): Shares fall 5% despite beating earnings estimates
IDEXX Laboratories (IDXX) shares dropped 5% despite beating first-quarter earnings estimates with $3.47 per share on $1.14 billion revenue. The decline is attributed to broader market volatility, investor caution regarding forward guidance, and concerns over slower InVue installations. Despite the stock trading at a discount to its fair value and analysts rating it a "Moderate Buy," near-term volatility is expected.
Resolute Holdings Management - Common Stock (NYSE:RHLD) Stock Quote
This article provides a stock quote and recent news for Resolute Holdings Management (NYSE: RHLD). The stock closed at 106.78, up 0.76%, on May 14, 2026. Key news includes recent earnings reports, executive appointments, and performance figures, with the stock showing a -42.7% YTD performance but a +55.6% 1-year performance.
IDEXX (IDXX) director Karen Peacock converts 101 RSUs into 102-share holding
IDEXX Laboratories director Karen Peacock converted 101 Restricted Stock Units (RSUs) into 101 shares of common stock on May 7, 2026, as a routine equity compensation event. This transaction increased her direct holdings to 102 shares of IDEXX common stock. No shares were sold, and the exercise price for the RSUs was $0.00 per share.
IDEXX Laboratories (NASDAQ: IDXX) director gains 257 shares from RSU vesting
IDEXX Laboratories director Daniel M. Junius acquired 257 shares of common stock through the vesting of Restricted Stock Units (RSUs) on May 7, 2026. This transaction increased his direct holdings to 3,561 shares. The event is a routine equity compensation and not an open-market purchase or sale.
IDEXX (IDXX) director’s RSUs vest into 257 shares, holdings updated
IDEXX Laboratories director Sophie V. Vandebroek recently had 257 restricted stock units (RSUs) vest, converting into 257 shares of common stock on May 7, 2026, as reported in a Form 4 filing. This transaction, executed at $0.00 per share, updated her direct holdings to 905 common shares and indirect holdings to 8,173 shares via the Sophie V. Vandebroek Revocable Trust. The filing noted no open-market purchases or sales, focusing solely on the equity compensation vesting and subsequent ownership adjustments.
Director at IDEXX Laboratories (IDXX) gains 339 shares from RSU vesting
IDEXX Laboratories director Lawrence D. Kingsley acquired 339 shares through the vesting and exercise of restricted stock units (RSUs) on May 7, 2026. This transaction involved 82 and 257 RSUs converting into common stock at a stated price of $0.00 per share, reflecting equity compensation rather than open-market trading. Following this, Kingsley directly holds 9,486 common shares.
IDEXX (IDXX) director Szostak adds 257 shares as RSUs vest into stock
IDEXX Laboratories director M. Anne Szostak acquired 257 shares of common stock on May 7, 2026, as restricted stock units vested at an exercise price of $0.00 per share. This transaction increased her direct common stock holdings to 519 shares, with additional indirect ownership through a trust and a family foundation. The event was a routine equity award vesting and did not involve any open-market sale.
BofA Sees Slower InVue Installations as Headwind for IDEXX Laboratories, Inc. (IDXX)
BofA Securities has lowered its price target for IDEXX Laboratories (IDXX) to $660 from $790 while maintaining a Neutral stance, citing concerns about the pace of InVue system installations and broader macroeconomic trends. Despite solid first-quarter operational performance, the firm noted weaker-than-expected placements. IDEXX, however, updated its fiscal 2026 outlook, raising revenue growth projections and emphasizing steady demand in its diagnostics business, particularly for advanced cancer detection tests for animals.
BofA Sees Slower InVue Installations as Headwind for IDEXX Laboratories, Inc. (IDXX)
BofA Securities has lowered its price target for IDEXX Laboratories (IDXX) from $790 to $660, maintaining a Neutral stance due to slower InVue system installations and macroeconomic uncertainties, despite solid first-quarter performance. Concurrently, IDEXX updated its fiscal 2026 outlook, raising reported revenue growth expectations to 8.6%–10.6% and projecting strong growth in its CAG Diagnostics recurring revenue and overall organic revenue. The company, a leader in veterinary diagnostics, continues to be recognized for its advanced cancer detection tests for animals.
IDEXX Laboratories Drops 5.8% Amid Sector-Wide Selling
IDEXX Laboratories experienced a 5.8% drop on Monday, with its stock falling to $527.42 amidst a broad selloff affecting the healthcare technology sector. This decline, which saw its market capitalization reduced to $41.6 billion, occurred without any clear company-specific news, regulatory announcements, or analyst downgrades. The coordinated downturn suggests broader sector-wide pressures, possibly due to institutional repositioning or concerns over valuation multiples, rather than issues specific to IDEXX.
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock decreased by 5.02% on Monday, closing at $532.00, despite a positive trading session for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains of 0.19%. This marks the third consecutive day of losses for IDEXX Laboratories Inc. shares.
Intuitive Surgical Drops 6.3% Amid Sector-Wide Selling
Intuitive Surgical's stock dropped 6.3% on Monday to $421.86, caught in a broad wave of selling across the medical technology sector. Despite no company-specific negative news, the robotic surgery leader experienced a significant decline, alongside peers like Edwards Lifesciences and IDEXX Laboratories, suggesting a macro or sentiment-driven market shift. The disproportionate fall raises questions about its premium valuation or higher volatility in a declining market.
Intuitive Surgical Drops 6.3% Amid Sector-Wide Selling
Intuitive Surgical (ISRG) saw its shares drop 6.3% to $421.86, outpacing other medical technology stocks in a sector-wide sell-off. Despite no company-specific news, the robotic surgery leader's decline suggests a macro or sentiment-driven shift, potentially due to broader portfolio repositioning or its premium valuation. Investors are advised to monitor sector weakness persistence and company-specific updates for future catalysts.
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock fell 2.11% on Friday, closing at $560.11, despite a positive trading session for the broader market indexes like the S&P 500 and Dow Jones Industrial Average. This marks the second consecutive day of losses for the company's shares.
Here’s Why IDEXX Laboratories Stock Could Deliver Around 11% Annual Returns Despite a 15% YTD Pullback
IDEXX Laboratories (IDXX) delivered strong Q1 2026 results with revenue up 14% and diluted EPS up 17%, and subsequently raised its full-year guidance. Despite a 15% year-to-date pullback, analysts project the stock could rise to around $763 per share by December 2028, representing an annualized return of approximately 11%. This positive outlook is driven by the company's expanding base of diagnostic instruments, recurring consumable revenues from companion animal testing, and sustained pricing power within the veterinary diagnostics market.
Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2026 Earnings Call Transcript
Elanco Animal Health (NYSE:ELAN) reported strong Q1 2026 results, exceeding expectations with 10% organic constant currency revenue growth and raised full-year guidance. The company attributed this success to its "Big 6" innovation products like Zenrelia and Credelio Quattro, which are driving market share gains across both pet and farm animal health sectors. Elanco also highlighted progress in its deleveraging efforts and expects continued margin expansion through its Elanco Ascend productivity initiative.
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Maintains Target Price $675
Stifel has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US) and maintained a target price of $675. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
Jefferies Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $729
Jefferies has reiterated its Buy rating for IDEXX Laboratories Inc (IDXX.US) but has adjusted its target price downwards to $729. This indicates continued confidence in the company's prospects despite a revision in valuation.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock advance by 2.89% to $579.23, outperforming major indices like the S&P 500 and Dow Jones Industrial Average. This strong performance ended a two-day losing streak for the company. The broader market also experienced a significant trading session with the S&P 500 rising 1.46% and the Dow Jones Industrial Average rising 1.24%.
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock decreased by 1.21% on Thursday, closing at $572.20, while the broader market also saw declines with the S&P 500 Index and Dow Jones Industrial Average falling. The company's stock is currently 25.69% below its 52-week high of $769.98 reached in November.
Jefferies Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $729
Jefferies has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US) but has adjusted its target price downwards to $729. This indicates a continued positive outlook on the company despite a revised valuation.
